Abstracts
Selenium in the treatment of radiation-associated secondary lymphedema
O. Micke, F. Bruns, R. Mücke, U. Schäfer, M. Glatzel, A.F. DeVries, K. Schönekaes, K. Kisters, and J. Büntzel
Price
42.00 $
Volume 21 p. 277 - 277
Abstract
O. Micke1,4, F. Bruns1,4, R. Mücke2,4, U. Schäfer1,4, M. Glatzel3,4, A.F. DeVries5, K. Schönekaes4, K. Kisters4,6 and J. Büntzel4,7
1Department of Radiotherapy, Münster University Hospital, Münster, 2Department of Radiotherapy, Radiation Oncology and Nuclear Medicine, Weiden Municipal Hospital, 3Department of Radiotherapy, Suhl Central Hospital, Suhl, 4German Working Group Trace Ele
Purpose: The aim of this explorative study was to evaluate the impact of selenium in the treatment of lymphedema after radiotherapy. Methods and materials: Between 6/1996 and 6/2001, 12 patients with arm edema and 36 with edema of the head and neck region were treated with selenium for therapy-related lymphedema. Of these 36 patients, 20 had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received sodium selenite for 4 – 6 weeks. Results: Self-assessment using a visual analogue scale (n = 48) showed a reduction of 4.3 points when comparing pre- and posttreatment values (p < 0.05). Of 20 patients with endolaryngeal edema, 13 underwent no, 5 a temporary and only 2 a permanent tracheostomy; 10 of 12 patients with arm edema showed a circumference reduction of the edematous limb and improvement in the skin fold index by 23.3 points. An improvement of one stage or more was shown by the Földi or the Miller score (n = 28) in 22 (Földi score) and in 24 (Miller score) patients. Conclusion: Treatment with sodium selenite is well-tolerated and easy to deliver. Additionally, our results suggest that sodium selenite has a positive effect on secondary developing lymphedema caused by radiation therapy alone or irradiation after surgery.
Originals
Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer – redox status data
J. Büntzel, O. Micke, R. Mücke, M. Glatzel, K.G. Schönekaes, U. Schäfer, K. Kisters and F. Bruns
Price
42.00 $
Volume 22 p. 211 - 215
Abstract
J. Büntzel1,3, O. Micke3, R. Mücke3, M. Glatzel2,3, K.G. Schönekaes3, U. Schäfer3, K. Kisters3 and F. Bruns3
1Department of Otolaryngology, Südharz Hospital, Nordhausen, 2Department of Radiotherapy, Central Hospital, Suhl, Germany, and 3The German Working Group “Trace Elements and Electrolytes in Radiation Oncology” (AKTE)
Objective: The supportive strategy of cytoprotection is based on the idea of scavanging free radicals in order to decrease side effects due to anticancer treatment. We have investigated amifostine and sodium selenite regarding its scavanging potential in head and neck cancer patients during radiochemotherapy. Material and methods: One hundred cancer patients received simultaneous radiochemotherapy. During irradiation, 31 patients (Group 1) got 500 µg sodium selenite per day, 29 patients (Group 2) got 500 mg amifostine, and 40 patients (Group 3) got 500 mg sodium selenite and 500 mg amifostine. Amifostine was given at days with chemotherapy only. We measured serum selenium concentration, activity of glutathione peroxidase and concentration of malondialdehyde at the beginning of radiotherapy, after three weeks and at the end of combined treatment. Results: We have seen differences in the serum selenium level of the patients regarding their tumor volume. Sodium selenite, in the amount of 500 mg, was able to correct decreased selenium concentrations within three weeks. The activity of glutathionperoxidase was increased when selenium was substituted. A reduction of malondialdehyde, e.g. aggressive free radicals, were seen in patients with selenium substitution and smaller tumors (Group 1) only. If the tumor volume was larger and the therapy more aggressive, the therapy-induced production of new free radicals was limited (Groups 2 and 3). The combination of sodium selenite and amifostine (Group 3) was more effective than the administration of amifostine alone (Group 2). Conclusion: The substitution of sodium selenite is able to reduce the endogenous level of aggressive free radicals in head and neck cancer patients. Further clinical studies are necessary to evaluate synergisms with other exogenous scavangers of free radicals (for example amifostine) and to evaluate the toxicity-limiting possibilities of this new supportive strategy.Correspondence to:
Dr. J. Büntzel
Klinik für HNO-Erkrankungen, Kopf-Hals-Chirurgie
Südharzkrankenhaus Nordhausen gGmbH
Dr.-Robert-Koch-Straße 39
99734 Nordhausen, Germany
Email: [email protected]
Originals
Sodium selenite in gynecologic radiation oncology – results of a prospective randomized observation study
R. Mücke, M. Glatzel, B. Reichl, R. Bernd-Skorka, J. Büntzel, F. Bruns, K. Kisters, F.J. Prott and O. Micke
Price
42.00 $
Volume 23 p. 173 - 177
Abstract
R. Mücke1,10, M. Glatzel2,10, B. Reichl3, R. Bernd-Skorka4, J. Büntzel5,10, F. Bruns6,10, K. Kisters7,10, F.J. Prott1 and O. Micke8,9,10
1Strahlentherapie am St. Josefs-Hospital Wiesbaden, 2Zentralklinikum Suhl, Klinik für Strahlentherapie, Suhl, 3Klinikum Weiden, Abteilung für Strahlentherapie, Radioonkologie und Nuklearmedizin, Weiden, 4Klinikum Neubrandenburg, Klinik für Strahlenther
Background: The aim of this prospective observation study was to evaluate, whether sodium selenite is able to compensate a preexisting selenium deficiency in adjuvant radiotherapy (RT) for pelvic gynecologic malignancies. Further, we proved the use of sodium selenite in the prevention of radiation induced diarrhoea. Patients and methods: Whole blood selenium levels were measured in patients undergoing adjuvant RT after curative surgical resection of a pelvic gynecologic tumor before RT, after completing 50% of RT, at the end of RT and six weeks after RT depending on the supplementation of sodium selenite in the verum group till the end of RT. Data were calculated for the patients who completed the study protocol. From 12/2000 to 12/2005 77 patients (median age: 65 years) completed the protocol. Results: All patients with histologically proven squamous cell and adenocarcinoma of the uterine cervix or corpus had decreased whole blood selenium levels. There is a significant increase of the mean level of whole blood selenium in the supplementation group reaching the lower border of the normal range and a decrease after cessation of selenium intake. In the control group we could not see any change of investigated mean selenium levels. Concerning diarrhoea, there has been a statistically significant difference between the study groups towards a lower incidence of diarrhea CTC 1/2 in week 5 with selenium supplementation (u-test, p=0.03). With a median follow up of 24 months (1-60) the actuarial 4 year overall survival rate of patients with supplementation of selenium was 96% compared to the control group with 71.6% (p = 0.1102). Conclusion: Our first data may serve as evidence for a successful selenium supplementation during radiotherapy of gynecological tumors. Selenium does not diminish the cytotoxic effect of radiation treatment.Correspondence to:
PD Dr. O. Micke
Klinik für Strahlentherapie und Radioonkologie
Franziskus Hospital
Kiskerstraße 26
33615 Bielefeld, Germany
Email: [email protected]
Originals
Selenium as radioprotector in head and neck cancer patients – first clinical results
J. Büntzel, M. Glatzel, K. Kisters, R. Mücke, F. Bruns, K. Schönekaes und O. Micke
Price
42.00 $
Volume 23 p. 178 - 180
Abstract
J. Büntzel, M. Glatzel, K. Kisters, R. Mücke, F. Bruns, K. Schönekaes und O. Micke
AKTE e.V., Bielefeld, Germany
Objective: A majority of radiotherapy patients is using complementary and alternative methods during anti-cancer treatment in order to improve the quality of life during this period. We investigate the influence of selenium substitution on the treatment toxicity (radiochemotherapy) in the group of head and neck cancer patients. Material and methods: 31 patients received concomittant radiochemotherapy (2 Gy Single dose, 60 Gy total dose, Week 1 and 5 with daily carboplatin 70 mg/m2 about 5 days) because of their squamous cell carcinoma of the ENT region. All patients had performed primary surgery of the basic tumor and the regional lymph nodes. Additionally the patients got sodium selenite orally (1,000 mg on the days of radiochemotherapy and 500 mg an the days of radiotherapy alone). Results: We observed severe mucositis in 7/31 (22%), severe xerostomia in 8/31 (26%), and resulting severe dysphagia in 2/31 (6%) of all patients. The Karnofsky performance status decreased from mean 85.5% to 30.4% at the end of radiochemotherapy. The median survival time was 21 month (range 2 – 62 month) after primary treatment. Conclusion: This first pilot investigation has shown decreased incidences and grades of typical toxicities as mucositis and xerostomia if selenium was substituted during the anticancer therapy. Further investigations are necessary to support this hypothesis.Correspondence to:
Dr. J. Büntzel
Department of Otolaryngology
Südharzkrankenhaus Nordhausen
Dr.-Robert-Koch-Strasse 39
99734 Nordhausen, Germany
Email: [email protected]
Originals
Scavenging of free radicals and the late toxicity of radiochemotherapy in head and neck cancer patients
J. Büntzel, M. Glatzel, R. Mücke, F. Bruns, K. Kisters and O. Micke
Price
42.00 $
Volume 23 p. 181 - 185
Abstract
J. Büntzel1,3, M. Glatzel2,3, R. Mücke3, F. Bruns3, K. Kisters3 and O. Micke3
1Department of Otolaryngology, Head and Neck Surgery, Südharzkrankenhaus Nordhausen gGmbH, Nordhausen, 2Department of Radiooncology, Zentralklinikum Suhl, Germany, 3German Working Group “Trace Elements and Electrolytes in Oncology” (AKTE)
Objective: We analyzed the late toxicity due to multimodal therapy of advanced head and neck cancers. The impact of cytoprotection with amifostine is the specific objective of this report. Methods: We included 851 patients (717 men, 134 women) with head and neck cancer into this prospective study. 519/851 had received amifostine before radio(chemo)therapy, 332 control subjects had not got any kind of cytoprotection before irradiation. A primary radiochemotherapy was performed in 282 patients, an adjuvant radiation was administered in 569 patients. The follow-up examination was done at our out-door department 21.4 months (median, range 2.3 – 149) after the primary therapy. Results: Late xerostomia was seen in 765/851 patients (89.9%). Altered taste was reported by 284/851 (33.5%). These symptoms were reduced significantly by amifostine. No influence were seen in interstitial lymph edema (48,4%) and stenosis of cervical esophagus (20.4%). Secondary symptoms like dysphagia (78.8%) were also reduced in trend. Conclusions: The administration of amifostine offers a opportunity to reduce selected long-time toxicity for survivors of head and neck cancer.Correspondence to:
Dr. J. Büntzel
Department of Otolaryngology
Südharzkrankenhaus Nordhausen
Dr.-Robert-Koch-Strasse 39
99734 Nordhausen, Germany
Email: [email protected]
Originals
Complementary and alternative medicine experience in radiation oncology patients: first results of a multi-center approach
F. Bruns, M. Glatzel, K. Schönekaes, D. Riesenbeck, R. Mücke, J. Büntzel, P. Micke, U. Schäfer, K. Kisters and O. Micke
Price
42.00 $
Volume 23 p. 318 - 325
Abstract
F. Bruns1, M. Glatzel2, K. Schönekaes3, D. Riesenbeck4, R. Mücke5, J. Büntzel6, P. Micke7, U. Schäfer4, K. Kisters8 and O. Micke4,9
1Department of Radiotherapy, Hannover Medical School, Hannover, 2Department of Radiotherapy, Central Hospital, Suhl, 3Department of Radiotherapy, Minden Hospital, Minden, 4Department of Radiotherapy and Radiation Oncology, Münster University Hospital, M
Background: In recent years the demand and use of complementary and alternative medicine (CAM) in malignant diseases has increased noticeably. Since the general knowledge about CAM use is scant and CAM could potentially interact with standard therapies the German Working group “Trace Elements and Electrolytes in Oncology” performed a multi-centric study to comprehensively evaluate the use of CAM therapies in cancer patients treated with radiotherapy. Methods: 1,013 patients receiving consecutively radiotherapy for malignant diseases were interviewed using a standardized questionnaire including clinical and pathological tumor parameters as well as the type of CAM and reasons for CAM use. A self-assessment of patients’ personal conditions was performed in order to evaluate the subjective impact of CAM on quality of life. Results: A total of 59% of patients reported using CAM therapies. CAM use was more common in female patients, generally higher in advanced stages of disease and most common in breast cancer patients. Most frequently reported CAM therapies were vitamins (18%), mistletoe extracts (15%), selenium (10%), and other trace element preparations (7%). Multivariate logistic regression showed age, gender, tumor type and stage, and smoking behavior to be significant predictors for CAM use. A subjective improvement in quality of life due to the use of CAM was accounted for in 30% of patients. Conclusions: More than half of patients undergoing RT for cancer are using CAM therapies. Therefore, radiation oncologists should be asking for respective obtaining information about CAM use in order to avoid harmful interactions with conventional therapies. The value and potential hazards of such combined treatments have yet to be tested in further clinical studies. Correspondence to:
Dr. F. Bruns
Department of Radiotherapy
Hannover Medical School
Carl-Neuberg-Straße 1
30625 Hannover, Germany
Email: [email protected]
Originals
Sodium selenite in gynecologic radiation oncology – first results of a phase III study
R. Mücke, M. Glatzel, D. Riesenbeck, R. Bernd-Skorka, G. Seifert, J. Büntzel, K.G. Schönekaes, F. Bruns, K. Kisters, and O. Micke
Price
42.00 $
Volume 21 p. 78 - 82
Abstract
R. Mücke1,9, M. Glatzel2,9, D. Riesenbeck3, R. Bernd-Skorka4, G. Seifert5, J. Büntzel6,9, K.G. Schönekaes9, F. Bruns7,9, K. Kisters8,9 and O. Micke3,9
1Strahlentherapie, Wiesbaden, 2Klinik für Strahlentherapie, Zentralklinikum Suhl, 3Klinik und Poliklinik für Strahlentherapie, Radioonkologie, Universitätsklinikum Münster, 4Klinik für Strahlentherapie, Klinikum Neubrandenburg, 5Klinik für Radioonko
Background: The aim of this prospective phase III study was to evaluate whether sodium selenite is able to compensate a preexisting selenium deficiency in adjuvant radiotherapy (RT) for pelvic gynecologic malignancies. Further, we proved the use of sodium selenite in prevention of radiation-induced diarrhea. Material and methods: Whole blood selenium levels were measured in patients undergoing adjuvant RT after curative surgical resection of a pelvic gynecologic tumor before RT, after completing 50% of RT, at the end of RT and 6 weeks after RT depending on supplementation of sodium selenite in the verum group till the end of RT. Data were calculated for the patients that completed study protocol. Results: From December 2000 to November 2002, 41 patients (median age: 64.5 years) completed the protocol. All patients with histologically proven squamous cell carcinoma and adenocarcinoma of the uterine cervix or corpus had decreased whole blood selenium levels. There is a significant increase of the mean level of whole blood selenium in supplementation group reaching the lower border of normal range and a decrease after cessation of selenium intake. In control group we could not see any change of investigated mean selenium levels. Concerning diarrhea, there is a non-significant trend towards a lower incidence of diarrhea CTC 2 with selenium supplementation at present. Conclusion: Our first data may serve as evidence for a successful supplementation of selenium during radiotherapy of patients with gynecological tumors. No selenium-related side effects were observed.
Original
Postoperative serum and whole blood selenium levels in patients with squamous cell and adenocarcinomas of the uterus after curative surgical treatment
R. Muecke, J. Buentzel, M. Glatzel, F. Bruns, K. Kisters, F.J. Prott, H. Schmidberger and O. Micke
Price
42.00 $
Volume 26 p. 78 - 82
Abstract
R. Muecke1,8, J. Buentzel2,8, M. Glatzel3,8, F. Bruns4,8, K. Kisters5,8, F.J. Prott1, H. Schmidberger6 and O. Micke7,8
1Department of Radiotherapy, St. Josefs-Hospital, Wiesbaden, 2Department of Otolaryngology, Municipal Hospital Nordhausen, 3Department of Radiotherapy, Municipal Hospital Suhl, 4Department of Radiotherapy and Radiooncology, Hannover Medical School, 5Clinic for Internal Medicine, St. Anna Hospital Herne, 6Department of Radiation Oncology and Radiation Therapy, University Mainz, 7Department of Radiotherapy, Franziskus Hospital Bielefeld, Germany and 8German Working Group Trace Elements and Electrolytes in Oncology
Background: The aim of this prospective study was to investigate levels of serum and whole blood selenium in patients with squamous cell and adenocarcinomas of the uterus after curative surgical treatment before radiation therapy (RT). Material and methods: Levels of serum and whole blood selenium were measured in patients before adjuvant RT after curative surgical resection of a pelvic gynecologic tumor. Blood selenium levels were measured using automated graphite furnace atomic absorption spectrophotometry. For the comparison of selenium levels, we used the recommended normal ranges of 65 – 135 µg/l for the serum, and 85 – 162 µg/l for the whole blood. For processing and statistical analysis of all data, the SPSS/PC Software package, version 15.0 (SPSS Inc. Chicago, IL, USA), was used. Results: Between 2001 and 2007, 126 patients (median age: 66 years) with uterine squamous cell (n = 17) or adenocarcinomas (n = 109) after curative surgical treatment were included. In 105/126 patients (83.3%), serum and whole blood selenium deficiency was found. The mean value of measured serum selenium levels was 62.9 ± 18.3 µg/l, and the mean value of measured whole blood selenium levels was 68.9 ± 18.6 µg/l. Mean levels of selenium were found to be significantly decreased in all patients in comparison to the recommended normal value for serum selenium (p < 0,001) and whole blood selenium (p < 0.001). There is no significant correlation between tumor-stage according to Federation Internationale de Gynecologie et d’Obstetrique (FIGO) and serum selenium (r = 0.09, p = 0.46), and whole blood selenium (r = -0.008, p = 0.94). Conclusion: This data revealed a quantitative decrease of nonenzymatic antioxidative capacities. The possibility of supplementation of selenium to compensate a selenium deficiency as soon as possible to improve quality of life during radiation therapy and reduce radiation-associated side effects should be proven in prospective randomized trials.Correspondence to:
Dr. O. Micke, PD; Klinik für Strahlentherapie und Radioonkologie, Franziskus Hospital, Kiskerstraße 26, 33615 Bielefeld, Germany
Email: [email protected]
Tumor
Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects
T. Hekmatara*, C. Bernreuther*, A.S. Khalansky, A. Theisen, J. Weissenberger, J. Matschke, S. Gelperina, J. Kreuter and M. Glatzel
Volume 28 p. 153 - 164
Abstract
T. Hekmatara1*, C. Bernreuther2*, A.S. Khalansky3, A. Theisen4, J. Weissenberger5, J. Matschke2, S. Gelperina6, J. Kreuter1 and M. Glatzel2
1Institute of Pharmaceutical Technology, J.-W. Goethe-University, Frankfurt/Main, 2Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3Institute of Human Morphology, Moscow, Russia, 4Zentrale Forschungseinrichtung, Klinikum Goethe-University, 5Neuro Science Center, Exp. Neurochirurgie, Frankfurt/Main, Germany, and 6Nanosystem Ltd., Moscow, Russia
The objective of this study was to investigate the therapeutic effects of doxorubicin bound to polysorbate-coated nanoparticles that had previously been shown to significantly enhance survival in the orthotopic rat 101/8 glioblastoma model. Tumor-bearing animals were subjected to chemotherapy using doxorubicin in solution (Dox-sol) or doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles (Dox-np) injected intravenously on Days 2, 5 and 8 post tumor implantation. The antitumor effect was assessed on Days 10, 14 and 18 post tumor implantation. Tumors showed signs of malignancy including invasion of brain tissue, brisk mitotic activity, microvascular proliferation, necrosis and increased proliferation resembling human glioblastoma. Dox-np produced a considerably more pronounced antitumor effect exhibited as a reduced tumor size, lower proliferation, and a decreased necrotic area compared to Dox-sol and to untreated control groups. A drastic effect of Dox-np on vascularization indicated an antiangiogenic mode of action.Correspondence to:
M. Glatzel, MD; Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
Email: [email protected]
Cellular mechanisms critical to lysosomal storage disease pathogenesis
Diagnosis of mucolipidoses, rapid purification of lysosomal enzymes and intracellular localization studies using a novel mannose-6-phosphate-specific single-chain antibody
T. Braulke, S. Müller-Loennies, G. Galliciotti and M. Glatzel
Price
42.00 $
Add to Cart
Login
###ENGLISH_ABSTRACT_LINK###
###FREE_ENGLISH_ARTICLE_DOWNLIAD_LINK###
Volume 48 p. 11 - 12
Abstract
T. Braulke, S. Müller-Loennies, G. Galliciotti and M. Glatzel
Proceedings: 7th International Symposium on Trace Elements in Human: New Perspectives, October 13 – 15, 2009, Athens, Greece
Selenium substitution during radiotherapy in head and neck cancer
J. Büntzel, O. Micke, M. Glatzel, U. Schäfer, D. Riesenbeck, K. Kisters, F. Bruns, K.G. Schönekaes, H. Dawczynski and R. Mücke
Price
42.00 $
Volume 27 p. 235 - 239
Abstract
Trace Elements and Electrolytes, Vol. 27 – No. 4/2010 (235-239)
Selenium substitution during radiotherapy in head and neck cancer
J. Büntzel1,8, O. Micke2,8, M. Glatzel3,8, U. Schäfer4,8, D. Riesenbeck5, K. Kisters6,8, F. Bruns7,8, K.G. Schönekaes8, H. Dawczynski9 and R. Mücke4,8
1Department of Otolaryngology, Head Neck Surgery, Südharz-Krankenhaus Nordhausen gGmbH, Nordhausen, 2Department of Radiotherapy, Franziskus-Hospital, Bielefeld, 3Department of Radiotherapy, Zentralklinikum Suhl GmbH, Suhl, 4Department of Radiotherapy, Klinikum Lippe-Lemgo, Lemgo, 5Department of Radiotherapy, Prosper-Hospital, Recklinghausen, 6Department of Internal Medicine I, St Anna Hospital, Herne, 7Department of Radiotherapy, Special Oncology, Medical School Hannover, Hannover, 8AKTE, The German Working Group “Trace Elements and Electrolytes in Oncology”, and 9Pharmaceutical company biosyn, Fellbach, Germany
Objective: The substitution of selenium effects in activation of the selenium dependent enzyme glutathione peroxidase which is important for scavenging free radicals. Until today only limited data was available about the clinical impact of selenium regarding the toxicities due to free radical producing therapies, e.g. irradiation or chemotherapy. Material and methods: 39 patients (8 female, 31 male) with advanced head neck cancer were included to a randomized Phase II study. The mean age was 63.52 ± 9.31 years. Tumor localizations: oral cancer 15 patients, oropharynx 19 patients, hypopharynx 5 patients, CUP 1 patient. Group A (n = 22) received 500 µg sodium selenite at the days of radiotherapy and 300 µg sodium selenite at holidays or weekend. Group B (17) was irradiated without any selenium substitution. Both groups were well balanced according age, gender, localization and stage of the tumor. We evaluated the RTOG grade of radiation-associated toxicities once per week. Results: We observed the following serious toxicities (Group A versus Group B): dysphagia 22.7% vs. 35.3%, loss of taste 22.7% vs. 47.1%, dry mouth 22.7% vs. 23.5%, and stomatitis 36.4% vs. 23.5%. A statistical trend (Fisher’s exact-test) is only seen in the area of loss of taste (p = 0,172). The analysis per week (Student t-test) had shown a significant reduction of dysphagia in the selenium group at the last week of irradiation. Conclusion: The small randomized trial has shown limited effects of selenium in the prevention of ageusia (loss of taste) and dysphagia due to radiotherapy because of head and neck cancer.Correspondence to:
PD Dr. med. J. Büntzel
Südharz-Krankenhaus Nordhausen GmbH
Dr.-Robert-Koch-Str. 39
99734 Nordhausen, Germany
Email: [email protected]
Proceedings: 7th International Symposium on Trace Elements in Human: New Perspectives, October 13 – 15, 2009, Athens, Greece
Trace elements selenium and zinc as tumor markers in patients with advanced head and neck cancer
J. Büntzel, U. Knolle, A. Garayev, R. Mücke, U. Schäfer, K. Kisters, K.G. Schönekaes, R. Hunger, F. Bruns, M. Glatzel and O. Micke
Price
42.00 $
Volume 27 p. 246 - 249
Abstract
Trace Elements and Electrolytes, Vol. 27 – No. 4/2010 (246-249)
Trace elements selenium and zinc as tumor markers in patients with advanced head and neck cancer
J. Büntzel1,4, U. Knolle1, A. Garayev1, R. Mücke2,4, U. Schäfer2,4, K. Kisters3,4, K.G. Schönekaes4, R. Hunger4, F. Bruns4,5, M. Glatzel4,6 and O. Micke4,7
1Department of Otolaryngology, Head Neck Surgery, Südharz-Krankenhaus Nordhausen gGmbH, Nordhausen, 2Department of Radiotherapy, Klinikum Lippe-Lemgo, Lemgo, 3Department of Internal Medicine I, St Anna Hospital, Herne, 4AKTE – The German Working Group “Trace Elements and Electrolytes in Oncology”, 5Department of Radiotherapy, Special Oncology, Medical School Hannover, Hannover, 6Department of Radiotherapy, Zentralklinikum Suhl gGmbH, Suhl and 7Department of Radiotherapy, Franziskus-Hospital, Bielefeld, Germany
During the last few years we have collected data showing a relation between status of the disease and the serum concentrations of different trace elements. Are they able to monitor the disease as tumor markers? In a first study 100 untreated head and neck cancer patients were characterized by decreased levels of selenium, zinc and iron. Copper was the only increased. During the radiotherapy no changes of serum concentrations were seen. A further analysis had shown the differences between resectable and non-resectable tumors. As larger primary tumors were examined, the concentration of selenium in the serum of our patients decreased. These findings are supported by new data of NMR-tumor volumetry and trace elements concentrations in 21 patients. The relation between serum-selenium and tumor volume is stronger than between classical tumor markers (SCC; CEA, CYFRA 21-1) and the tumor volume. A last investigation has suggested that a destroyed homeostasis of trace elements is a sign of a pre-terminal ill patient. When the destroyed homeostasis is observed, the patient has a window of 4 – 6 weeks of remaining life time. Conclusions: Trace element status offers a lot of information about the course of the disease and the individual. But environmental factors have more impact on this trace element status than on other classical tumor markers.Correspondence to:
PD Dr. J. Büntzel
Südharz-Krankenhaus Nordhausen GmbH
Dr.-Robert-Koch-Str. 39
99734 Nordhausen, Germany
Email: [email protected]
Proceedings: 7th International Symposium on Trace Elements in Human: New Perspectives, October 13 – 15, 2009, Athens, Greece
Complementary and alternative medicine (CAM) use in terminally ill patients
J. Büntzel, H. Büntzel, O. Micke, K. Kisters, F. Bruns, M. Glatzel, R. Mücke, K.G. Schönekaes and U. Schäfer
Volume 28 p. 49 - 51
Abstract
Trace Elements and Electrolytes, Vol. 28 – No. 1/2011 (49-51)
Complementary and alternative medicine (CAM) use in terminally ill patients
J. Büntzel1,8, H. Büntzel2, O. Micke3,8, K. Kisters4,8, F. Bruns5,8, M. Glatzel6,8, R. Mücke7,8, K.G. Schönekaes8 and U. Schäfer7,8
1Department of Otolaryngology, Head Neck Surgery, Südharz-Krankenhaus Nordhausen gGmbH, Nordhausen, 2Department of Palliative Medicine, Südharz-Krankenhaus Nordhausen gGmbH, Nordhausen, 3Department of Radiotherapy, Franziskus-Hospital, Bielefeld, 4Department of Internal Medicine I, St. Anna-Hospital, Herne, 5Department of Radiotherapy, Special Oncology, Medical School Hannover, Hannover, 6Department of Radiotherapy, Zentralklinikum Suhl gGmbH, Suhl, 7Department of Radiotherapy, Klinikum Lemgo-Lippe, Lemgo, Germany and 8AKTE - The German Working Group “Trace Elements and Electrolytes in Oncology”
Objective: The use of complementary and alternative methods is common in oncology, but nothing is known about the role of CAM in the last days of a patient’s life. Material and methods: Between 1-2007 and 10-2008 the palliative care team treated 85 patients (50 male, 35 female, median age 62 years) on out-door basis. All families were asked to complete a structured questionnaire regarding the use of CAM during the last period of the patient’s life. Patients suffered from cancer in 83/85 patients (98%), 2 patients had neurologic disorders. Results: Only 20 families (31%) have not used any CAM. Spiritual support (praying, hospice services) was asked for by 60/85 families (71%). 25/85 families (29%) reported drug use. Favorite methods were vitamins (n = 11, 13%), trace elements (n = 9, 11%), and mistletoe (n = 8, 9%). 30 patients (35%) were treated by physiotherapy (28 oncology patients, 2 neurology patients). Logopedy and ergotherapy were used in 10 patients (12%). 12 families (14%) reported use of aroma-therapy in patient’s care. The main information source was the GP (house physician) (45/85, 53%)), followed by the palliative care team (30/85, 35%) and pharmacies (27/85, 32%). Internet, journals or self-service information were only used by 25/85 families (29%). The effectivity of the categorized methods was estimated between 1 and 5 (very good - worthy) by the patients or their families. The following ranking was registered: spiritual support 2.4; physical therapy 2.7, logopedy/ergotherapy 3.1, drugs 3.3. 65/85 families (76%) were satisfied with the information received from the health care practitioners. Conclusion: Complementary methods are often practiced during the last days of a patients life. Families and friends are looking for valid information and need help from the professionals. The different methods have been evaluated regarding effectivity as well as acceptance by the patients.Correspondence to:
PD Dr. med. J. Büntzel
Südharz-Krankenhaus Nordhausen GmbH
Dr.-Robert-Koch-Str. 3
99734 Nordhausen, Germany
Email: [email protected]
Original
Selenium substitution during radiotherapy of solid tumors
J. Büntzel, O. Micke, K. Kisters, F. Bruns, M. Glatzel, K. Schönekaes, G. Kundt, U. Schäfer and R. Mücke
Price
42.00 $
Volume 28 p. 101 - 104
Abstract
Trace Elements and Electrolytes, Vol. 28 – No. 2/2011 (101-104)
Selenium substitution during radiotherapy of solid tumors
J. Büntzel1, O. Micke2, K. Kisters3, F. Bruns4, M. Glatzel5, K. Schönekaes3, G. Kundt6, U. Schäfer7 and R. Mücke7
1Department of Otolaryngology, Head Neck Surgery, Suedharz-Krankenhaus, Nordhausen, 2Department of Radiotherapy, Franziskus Hospital, Bielefeld, 3German Study Group “Trace Elements and Electrolytes in Onclogy” (AKTE), 4Department of Radiotherapy, Specialized Oncology, Medical School Hannover, 5Department of Radiotherapy, Zentralklinikum, Suhl, 6Institute of Medical Statistics, University Rostock, and 7Department of Radiotherapy, Klinikum Lemgo-Lippe, Lemgo, Germany
Background: The trace element Selenium is an essential cofactor of the enzyme glutathioneperoxidase (GSH-Px), which is important for the endogenous detoxification of free radicals. A reduced activity of GSH-Px is related to increased toxicities due to radiation therapy during primary cancer treatment. Therefore, selenium substitution may be a new supportive strategy to diminish radiation-associated side effects. Two observation studies were conducted to get experiences in selenium substitution during ongoing irradiation. Material and methods: The selenium blood concentrations of 121 radiotherapy-patients were measured in two randomized observation studies (81 gynecological tumors, 40 head and neck tumors). Measurements (atom absorption spectrometry) were performed in serum and whole blood (WB) samples before, at the half, at the end, and 6 weeks after radiotherapy. In case of decreased selenium levels in WB, 63 patients (mean age 63.83 ± 9.23 y) received selenium substitution (500 µg sodium selenite at RT-days, 300 µg at weekend) and 64 patients (mean age 63.03 ± 10.47 y) were evaluated as control group without any selenium substitution. Both groups were well balanced according to tumor localization and stage. Reference values were 85 – 162 µg/l WB-selenium, and 65 – 135 µg/l serum-selenium. Results: We measured the following WB selenium (Se) levels (Se-group vs. control group, U-test): beginning RT 64.17 ± 13.98 µg/l vs. 64.50 ± 14.47 µg/l (p = 0.869); half RT 92.48 ± 26.68 µg/l vs. 65.80 ± 18.04 µg/l (p < 0.001); end RT 93.78 ± 25.90 µg/l vs. 64.06 ± 17.54 µg/l (p < 0.001); 6 weeks after RT 74.01 ± 20.06 µg/l vs. 69.66 ± 17.83 µg/l (p = 0.183). The serum levels were as follows: beginning RT 59.18 ± 13.49 µg/l vs. 61.99 ± 15.72 µg/l (p = 0.427); half RT 104.75 ± 31.41 µg/l vs. 62.37 ± 16.23 µg/l (p < 0.001); end RT 100.63 ± 31.12 µg/l vs. 62.29 ± 16.11 µg/l (p < 0.001); 6 weeks after RT 72.73 ± 26.53 µg/l vs. 64.17 ± 17.22 µg/l (p = 0.170). Conclusion: The used dosage of 500 µg sodium selenite per day is sufficient to treat the selenium deficiency during radiotherapy. After the end of substitution the patient returns to his individual selenium status.Correspondence to:
PD Dr. med. J. Büntzel
Dept. of Otolaryngology, Head Neck Surgery
Südharz-Krankenhaus Nordhausen GmbH
Dr.-Robert-Koch-Str. 39
99734 Nordhausen, Germany
Email: [email protected]
Editorial
Treatment of hot flushes in tumor patients with hormonal deprivation by magnesium – new aspects of a forgotten cation in oncology
O. Micke, R. Hunger, J. Büntzel, R. Mücke, M. Glatzel and K. Kisters
Add to Cart
Login
###ENGLISH_ABSTRACT_LINK###
###FREE_ENGLISH_ARTICLE_DOWNLIAD_LINK###
Volume 28 p. 139 - 142
Abstract
Treatment of hot flushes in tumor patients with hormonal deprivation by magnesium – new aspects of a forgotten cation in oncology
O. Micke, R. Hunger, J. Büntzel, R. Mücke, M. Glatzel and K. Kisters